We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$328M
AUM Growth
-$33M
Cap. Flow
-$50.7M
Cap. Flow %
-15.44%
Top 10 Hldgs %
48.5%
Holding
63
New
10
Increased
14
Reduced
12
Closed
20

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$8.86M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$8.46M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.89M
4
VRML
Vermillion, Inc.
VRML
+$4.93M
5
ARVN icon
Arvinas
ARVN
+$4.62M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10.4M
3
NVTA
Invitae Corporation
NVTA
+$10.3M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$9.31M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$701M
$5.75M 1.75%
+525,400
New +$5.89M
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$5.12B
$5.35M 1.63%
200,000
– –
ARVN icon
28
Arvinas
ARVN
$604M
$4.84M 1.47%
+220,000
New +$4.62M
VRML
29
DELISTED
Vermillion, Inc.
VRML
$3.78M 1.15%
+4,250,000
New +$4.93M
ZYME icon
30
Zymeworks
ZYME
$2.07B
$3.74M 1.14%
170,000
+115,000
+209% +$2.11M
SBBP
31
DELISTED
Strongbridge Biopharma plc.
SBBP
$3.57M 1.09%
1,140,000
-12,500
-1% -$45.9K
VKTX icon
32
Viking Therapeutics
VKTX
$3.95B
$3.32M 1.01%
400,000
-85,000
-18% -$726K
AIMT
33
DELISTED
Aimmune Therapeutics
AIMT
$2.71M 0.83%
130,000
-35,000
-21% -$721K
AQST icon
34
Aquestive Therapeutics
AQST
$648M
$2.48M 0.76%
+590,000
New +$3.02M
THOR
35
DELISTED
Synthorx, Inc. Common Stock
THOR
$2.13M 0.65%
157,600
+117,600
+294% +$1.89M
RARX
36
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.53M 0.47%
+51,000
New +$1.17M
FENC icon
37
Fennec Pharmaceuticals
FENC
$413M
$1.18M 0.36%
295,000
-335,000
-53% -$1.42M
ARQL
38
DELISTED
Arqule Inc
ARQL
$1.1M 0.34%
+100,000
New +$696K
CRNX icon
39
Crinetics Pharmaceuticals
CRNX
$9B
$900K 0.27%
36,000
-37,000
-51% -$916K
PLX icon
40
Protalix BioTherapeutics
PLX
$210M
$469K 0.14%
+100,000
New +$423K
GRDX
41
GridAI Technologies Corp
GRDX
$28.6M
$247K 0.08%
+1
New +$286K
BLRX
42
BioLineRX
BLRX
$12.1M
$91K 0.03%
417
– –
ABEO icon
43
Abeona Therapeutics
ABEO
$345M
– –
-22,400
Closed -$4.12M
APLS
44
DELISTED
Apellis Pharmaceuticals
APLS
– –
-115,000
Closed -$2.24M
ASND icon
45
Ascendis Pharma A/S
ASND
$16.4B
– –
-95,000
Closed -$11.2M
CDTX
46
DELISTED
Cidara Therapeutics
CDTX
– –
-50,000
Closed -$2.65M
CPRX
47
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-1,825,000
Closed -$9.31M
ESTA icon
48
Establishment Labs
ESTA
$2.14B
– –
-50,000
Closed -$1.2M
KURA icon
49
Kura Oncology
KURA
$1.17B
– –
-25,200
Closed -$418K
LQDA icon
50
Liquidia Corp
LQDA
$6.26B
– –
-225,000
Closed -$2.56M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2019 Portfolio in Review

As of Q2 2019, Opaleye Management held 63 positions worth $328M, down 9.1% from $361M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management withdrew a net $50.7M in Q2 2019, closing 20 positions and reducing 12 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Lexicon Pharmaceuticals worth $9.31M.

  • Opaleye Management's largest Q2 2019 buy was Lexicon Pharmaceuticals: 1,480,000 shares worth $9.31M.
  • Opaleye Management added most to Ocular Therapeutix in Q2 2019, an estimated $3.89M increase.
  • Opaleye Management's biggest Q2 2019 reduction was Axogen, cutting an estimated $4.28M.
  • Opaleye Management fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $11.2M.
  • Opaleye Management's ten largest holdings make up 49% of its $328M portfolio in Q2 2019.
  • Opaleye Management opened 10 new positions and closed 20 in Q2 2019.
  • Opaleye Management's portfolio value fell 9.1% quarter-over-quarter to $328M.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.